Geographic and temporal trends of transmitted hiv-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe

HIV Clinical Trials

Volumn 10, Issue 2, 2009, Pages 94-103

  Rahim, Sibtain ^a   Fredrick, Linda M ^a   Da Silva, Barbara A ^a   Bernstein, Barry ^a   King, Martin S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antiretrovirals; Non nucleoside reverse transcriptase inhibitor; Protease inhibitor; Transmitted drug resistance

Indexed keywords

AMINO ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTIRETROVIRUS AGENT; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NORTH AMERICA; PRIORITY JOURNAL; SCREENING TEST; SEQUENCE ANALYSIS; VIRUS MUTATION; VIRUS TRANSMISSION; WESTERN EUROPE; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECT; EUROPE; GENETICS; GEOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL; TIME; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTI-RETROVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; GENOTYPE; GEOGRAPHY; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; NORTH AMERICA; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; YOUNG ADULT;

EID: 68149110352     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1002-94     Document Type: Article

References (48)

1. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J. 1999;160(5):659-665.
2. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378-384.
3. Daar ES, Richman DD. Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses. 2005;21(5):343-357.
4. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of HIV-1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility. J Infect Dis. 1999;179:1375-1381.
5. Zolopa AR, Shafer RW, Warford A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813-821.
6. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394.
7. Peuchant O, Thiebaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first line antiretroviral therapy. AIDS. 2008;22(12):1417-1423.
8. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59:1047-1056.
9. Truong HML, Klausner JD, Hecht FM, et al. Reduced levels of primary resistance to nRTIs in San Francisco is discernable using two independent sentinel populations. Antivir Ther. 2006;11:S115.
10. Smith D, Moini M, Pesano R, et al. Clinical utility of HIV standard genotyping among antiretroviral-naïve individuals with unknown duration of infection. Clin Infect Dis. 2007;44:456-458.
11. Ross LL, Florance A, Wine B, et al. Prevalence of HIV-1 drug resistance-associated mutations in a large cohort of antiretroviral therapy (ART) naïve HIV-infected individuals in the United States from 2000-2004. Antivir Ther. 2006;11:S119.
12. Martinez-Picado J, Gutierrez C, de Mendoza C, et al. Surveillance of drug resistance and HIV subtypes in newly diagnosed patients in Spain during 2004. Antivir Ther. 2005;10:S137.
13. Kucherer C, Poggensee G, Korn K, et al. High level of resistance HIV-1 in newly diagnosed patients both with documented seroconversion and with unknown date of infection. In: Program and abstracts of the Fourth European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, France. Abstract 10.
14. Oette M, Kaiser R, Daumer M, et al. Trends of primary drug resistance in chronically HIV-infected patients in Germany, 2001-2005. Antivir Ther. 2006;11:S125.
15. Wensing AMJ, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966.
16. Agwale SM, Zeh C, Paxinos E, et al. Genotypic and phenotypic analyses of human immunodefi ciency virus type 1 in antiretroviral drug-naïve Nigerian patients. AIDS Res Hum Retroviruses. 2006;22:22-26.
17. Vidal N, Mulanga C, Bazepo S, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202-206.
18. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 2002;288(2):181-188.
19. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodefi ciency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis. 1997;175(6):1502-1506.
20. Pillay D. Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. Antivir Ther. 2004;9(5):695-702.
21. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identifi cation of drug resistance mutations in the human immunodefi ciency virus type 1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-2296.
22. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping profi ciency program. AIDS Res Hum Retroviruses. 2002;18:243-248.
23. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005;19:1819-1825.
24. Johnson JA, Li J-F, Brant A, et al. Multi-drug resistant HIV-1 are transmitted more frequently than current estimates. Antivir Ther 2005;10:S124.
25. Johnson J, Li JF, Brant A, et al. Sensitive drug-resistance testing reveals a greater prevalence of transmitted multidrug- resistant HIV-1 than previously estimated. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, CO. Abstract 642.
26. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med. 2007;15(4):119-125.
27. Shafer RW, Rhee SY, Pillay D, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007;21(2):215-223.
28. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198(2):234-240.
29. Gathe J, da Silva BA, Cohen DE, et al. A once daily lopinavir/ritonavir based regimen is non-inferior to twice daily dosing and results in similar safety and tolerability in antiretroviral naïve subjects through 48 weeks. JAIDS. 2009; 50(5):474-1481.
30. Cane P, Chrystie I, Dunn D, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 2005;331(7529):1368.
31. US Food and Drug Administration. FDA approves nevirapine to treat HIV. June 24, 1996. Available at: http://www. fda.gov/bbs/topics/ANSWERS/ANS00742. html. Accessed February 3, 2008.
32. Viramune® approved by European Commission for treatment of HIV. Boehringer Ingelheim Press Release. February 10, 1998. Available at: http://www.boehringer-ingelheim. com/hiv/archive/adetail.asp?ID=56. Accessed February 3, 2008.
33. AIDS epidemic update. Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2007. December 2007; 1-50. Available at: http://data. unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf. Accessed February 1, 2009.
34. de Mendoza C, Rodriguez C, Eiros JM, et al. Antiretroviral recommendations may infl uence the rate of transmission of drug-resistant HIV type 1. Clin Infect Dis. 1995;21:556-560.
35. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drugresistant HIV in Denmark during 1997-2004. Antivir Ther. 2006;11:591-600.
36. European Public Assessment Reports (EPARs) for authorized medicinal products for human use, Norvir. European Medicines Agency (EMEA). August 26, 1996. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/norvir/ norvir.htm. Accessed February 8, 2009.
37. Turner D, Brenner B, Routy JP, et al. Diminishing representation of HIV-1 variants containing select drug-resistanceconferring mutations in primary HIV-1 infection. J Acquir Immune Defi c Syndr. 2004;37:1627-1631.
38. Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drugresistant mutations in seroconverters. Antivir Ther. 2006;11:329-334.
39. Nicastri E, Sarmati L, d'Ettore G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol. 2002;69:1-6.
40. Leigh Brown AJ, Frost SD, Mathews C, et al. Transmission fitness of drug-resistant human immunodefi ciency virus and the prevalence of resistance in the antiretroviraltreated population. J Infect Dis. 2003;187:683-686.
41. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther. 2006;11:173-178.
42. Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. New Engl J Med. 2008;358:1590-1602.
43. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006:20:701-710.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultsandAdolescentGL.pdf. Accessed February 1, 2009.
45. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe. October 2008; 1-17. Available at: http://www.eacs.eu/guide/1-Treatment-of-HIV-Infected-Adults.pdf. Accessed February 1, 2009.
46. Beddows S, Galpin S, Kazmi SH, et al. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes. J Med Virol. 2003;70:337-342.
47. Tong CYW, Mullen J, Kulasegaram R, et al. Genotyping of B and non-B subtypes of human immunodefi ciency virus type 1. J Clin Microbiol. 2005;43(9):462-467.
48. Pandit A, Mackay WG, Steel C, et al. HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 genotyping profi ciency programme. J Clin Virol. 2008;43:401-406.